FM1® Test
← Back to Blog

Genetic Testing for Fibromyalgia: What DNA Can Tell You

Geometric illustration contrasting inherited and active DNA signals

A genetic test for fibromyalgia can mean two different things, and the difference matters. One looks at the DNA you were born with to estimate risk. The other looks at DNA-level changes in your immune system that show up in your blood. The FM1® Test is the second kind: a blood draw that uses DNA science to identify genomic signatures tied to fibromyalgia, chronic pain and fatigue. Below, you’ll see what the gene research shows, where it stops, and how a blood-based signature gives you objective evidence to bring to your doctor.

Fm1test
fm1test.com
Bring DNA Evidence to Your Doctor
The FM1® Test uses a quick blood draw to identify immune system DNA signatures related to fibromyalgia, chronic pain, and fatigue.
Visit

TL;DR

  • Studies of inherited gene variants (HTT, COMT and others) describe who may be more susceptible. They do not tell you whether you have fibromyalgia today.
  • Fibromyalgia runs in families, yet genes alone do not decide who develops it.
  • The FM1 Test takes a different route: a quick blood draw that looks for DNA genomic signatures of immune system changes.
  • The test is Medicare- and insurance-covered, results come within about a week, and positive respondents are offered a no-cost clinical trial.
  • Your doctor still makes the diagnosis from your symptoms and history. Objective results give that conversation something solid to work from.

Table of Contents

Two kinds of DNA testing, two different questions

When people search for a DNA test for fibromyalgia, they usually want one thing: proof that the pain and exhaustion are real. The term “genetic test” covers very different tools, so it helps to separate them.

Inherited-variant testing reads the DNA sequence you were born with. It looks for small differences, called polymorphisms, in specific genes. Because they are inherited, they say something about susceptibility. They cannot show what your body is doing right now.

Genomic signature testing looks at how genes are behaving in your blood cells. It captures patterns of activity linked to immune system changes. This is the approach behind the FM1 Test. Our test is designed to identify specific DNA genomic signatures in positive patients, signatures that we report are not found in other disorders or in healthy people.

The first kind is mostly a research tool. The second is built to give a patient and a clinician something measurable.

Two kinds of DNA testing, two different questions

What the gene research has found so far

The scale of recent research is worth knowing, because it validates what many patients have said for years: fibromyalgia has a biological basis.

The largest genetic study to date

A multi-ancestry study in Nature Medicine, published 28 July 2026, analyzed 2,563,755 people, including 54,629 with fibromyalgia, and identified 26 risk loci (regions of DNA linked to the condition). Variants were found in or near genes such as HTT, GPR52, DCC, DRD2/NCAM1, MDGA2, CELF4, CAMKV, MST1R and MAML3. The strongest association was a coding variant in HTT, which carries about 9% higher odds of fibromyalgia (OR = 1.09).

Key figures from a large fibromyalgia genetics study

The authors also found that the genetic signal was concentrated in nervous-system tissues and cell types. That points to fibromyalgia as a biologically real, nervous-system-related disorder rather than something imagined.

What a 9% increase means in practice

An odds ratio of 1.09 is a small nudge. Many people carry such variants and never develop fibromyalgia, and many people with fibromyalgia do not carry them. According to the University of Toronto’s Temerty Faculty of Medicine, the study found that genetics is not the main determinant of who develops fibromyalgia. Even people with many risk variants likely need another trigger, such as a painful arthritic condition.

So these variants are signposts to the biology. They are not a verdict on any one person.

The COMT gene

One of the most studied genes is COMT, which helps break down chemical messengers involved in pain and stress. A 2024 study in the journal PAIN compared 294 people with fibromyalgia to 209 healthy controls. It found that the G/G (Val/Val) version of the gene was associated with about twice the risk of fibromyalgia compared with A/A (Met/Met). Among patients, the A/A version was linked with more severe pain. The authors describe pairing genetic and clinical profiles as a step toward more tailored treatment.

Family history: real, but not destiny

If your mother, sister or aunt has fibromyalgia, you may wonder whether you are fated to follow. A 2023 review reports that the risk of developing fibromyalgia is eightfold higher among first-degree relatives (parents, siblings and children). A 2021 review reports that genetic factors may account for up to 50% of vulnerability.

Those figures explain why family history gets attention at the doctor’s office. They also show why a family tree is a clue rather than an answer. Environment, infections, injuries and stress all play a part, and the combination differs from person to person. Our article on whether fibromyalgia is genetic goes deeper on the family link.

Why risk genes do not answer “do I have it?”

A gene variant tells you about the starting line. It does not tell you whether the body has changed. The 2021 review notes that current genetic analyses can indicate a predisposition. Anyone living with daily pain wants a different answer: does something measurable explain my symptoms?

The same is true for broad chronic-pain genetics. A 2025 literature review estimates that DNA differences account for about 70% of individual differences in pain sensitivity. It adds that only a few studies offer randomized-trial-level evidence for specific genes, so this information is not yet routinely guiding care. That is an honest description of where inherited-variant research stands: promising, and still building.

Single-gene panels belong in this category. MTHFR testing, for example, looks at one gene involved in how the body processes certain nutrients. It is a different kind of test with a different purpose than an assessment built around fibromyalgia-related immune changes.

Genes that guide medication

There is one area where gene testing already has controlled-trial support: choosing pain medicines. A 2023 randomized, double-blind study of 60 chronic pain patients used CYP2D6, OPRM1 and COMT genotypes to guide opioid therapy. The genotype-guided group had better pain relief and quality of life, fewer clinically relevant adverse events and a 42% lower opioid dose than the group on usual prescribing.

This is pharmacogenetics. It asks how your body handles a drug. It is separate from asking whether fibromyalgia explains your symptoms. If you take or are considering opioids, discuss any such testing with your prescribing doctor or pharmacist, and never change a dose on your own.

How fibromyalgia is diagnosed today

Most people reach fibromyalgia the long way: months or years of appointments, normal-looking routine labs and the sense of not being believed. The Arthritis Foundation explains that diagnosis rests mainly on symptoms, medical history and a physical exam, with lab tests often used to rule out other conditions. The Canadian Fibromyalgia Guidelines list the usual rule-out labs: a full blood count, erythrocyte sedimentation rate, C-reactive protein, creatine kinase and thyroid stimulating hormone. They also note growing evidence that many genes, working together, play a role.

A 2026 review says fibromyalgia should be diagnosed positively using the ACR 2010/2016 criteria, not by exclusion. In plain terms: widespread pain, fatigue, sleep trouble and thinking difficulties, scored on a standard questionnaire and exam. If you want to understand that process, see our guides to how doctors diagnose fibromyalgia and what to expect during a diagnosis.

This is where objective data earns its place. The criteria depend on how you describe your symptoms. A blood-based result adds a measurement that does not depend on how well you can put pain into words.

What the FM1 Test adds

The FM1 Test is a blood test that uses DNA science to identify immune system changes related to fibromyalgia, chronic pain and fatigue. Here is what we say about it:

  • Objective evidence. It identifies specific DNA genomic signatures in positive patients. We designed it to confirm fibromyalgia as a legitimate medical condition, not just a syndrome.
  • A simple process. It requires a quick blood draw at a local facility.
  • Speed. Results are available within about a week.
  • Coverage. The test is Medicare- and insurance-covered.
  • Clinical trial access. Positive respondents are offered a no-cost clinical trial.

For a patient who has been told it is stress, aging or “just pain,” a result tied to a measurable biological signature can be validating. For a clinician, it is an additional data point to sit alongside the exam and the criteria.

Who benefits from looking into it

If you have chronic pain or fatigue without answers. You have likely had the standard labs. A signature-based test is built to look where routine panels do not.

If you are skeptical. Doubt is reasonable. Fibromyalgia has long been questioned, which is why objective, DNA-level evidence matters. The gene research above shows the science is moving toward biology, and our test is built on that direction.

If you are a healthcare provider. You need dependable ways to support a diagnosis and explain it to patients. Our guide to diagnostic tests for fibromyalgia outlines what exists and what to ask, and the FM1 Test FAQ covers ordering and logistics.

If you are unsure whether now is the time, read seeking a fibromyalgia diagnosis: when to test and is a fibromyalgia test right for you.

A practical path from symptoms to answers

  1. Write down your pattern. Note where the pain is, how long it has lasted, how fatigue and sleep behave, and any family history of fibromyalgia or autoimmune disease. A 2026 Swedish study of more than six million twins and siblings, from the University of Groningen, found fibromyalgia’s strongest genetic correlation was with immune-mediated diseases, so mention those too.
  2. See your doctor. Rule-out labs and a clinical evaluation remain the foundation, and your doctor should check for other causes of your symptoms.
  3. Get objective evidence. Ask about the FM1 Test, or start the order yourself.
  4. Review the result with your clinician. A positive result can support a diagnosis conversation and opens the door to the no-cost clinical trial.

Perspective

We built the FM1 Test because we kept hearing the same story: real pain, real fatigue, and a long road of being told nothing was wrong. The gene studies published in recent years are encouraging, because they confirm that fibromyalgia has a biological footprint. Inherited variants describe susceptibility, though, and patients need more than a probability.

That is why we focus on DNA genomic signatures of immune system changes in the blood. A quick blood draw, results within about a week and coverage through Medicare and insurance put objective evidence within reach. Positive respondents are also offered a no-cost clinical trial, so a result can lead somewhere.

Our view is simple: you should not have to argue for the legitimacy of your own symptoms.

the author

Take the next step

If you want objective, DNA-based evidence for what you are living with, the FM1 Test is a blood draw at a local facility, with results in about a week and coverage through Medicare and insurance.

Fm1test

You can start your FM1 Test here or learn more on the FM1 Test home page. If you have already taken it, you can share your experience to help others decide.

FAQ

Is there a genetic test for fibromyalgia?

Yes, in the sense that a blood test can look for DNA genomic signatures linked to fibromyalgia. The FM1 Test does this, identifying immune system changes through DNA science. Inherited-variant studies are a separate line of research that describes risk.

Which genes are linked to fibromyalgia?

The 2026 Nature Medicine study found 26 risk loci, with the strongest signal in HTT, along with GPR52, DCC, DRD2/NCAM1 and others. COMT is among the most studied individual genes. Each variant has a small effect on its own.

Does a genetic test for chronic pain work the same way?

Not exactly. Pharmacogenetic tests such as CYP2D6 and COMT panels help doctors choose and dose pain medicines. They answer a medication question rather than a fibromyalgia question. Talk to your prescriber before acting on any such result.

Will my insurance cover the FM1 Test?

The FM1 Test is Medicare- and insurance-covered. The FM1 Test FAQ page explains the ordering process, and our team can help you with coverage questions.

What happens if my result is positive?

A positive result gives you objective evidence to share with your clinician. Positive respondents are also offered a no-cost clinical trial.

Sources

Apply Now